News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
CRISPR, the gene-editing technology that could revolutionise biologics, is set to become a patent battleground as companies vie over who owns the tool and its products, says an intellectual property expert.
Scotland-based TC BioPharm has completed its work on a clinical manufacturing facility in Glasgow.
USP (US Pharmacopeia) is offering its support for efforts from the WHO to develop a global approach to the naming of all biologics.
SAFC and Baxter’s BioPharma unit are working together to contract manufacture ADCs (antibody drug conjugates) for biopharma companies.
Novartis has shipped the first of its cell-culture - rather than chicken egg - based vaccines for the 2014-2015 flu season from its North Carolina facility.